ARTICLE

Received 21 Mar 2012 | Accepted 2 Aug 2012 | Published 4 Sep 2012

DOI: 10.1038/ncomms2046

Efficacy of the β_2 -adrenergic receptor is determined by conformational equilibrium in the transmembrane region

Yutaka Kofuku^{1,2}, Takumi Ueda¹, Junya Okude¹, Yutaro Shiraishi¹, Keita Kondo¹, Masahiro Maeda³, Hideki Tsujishita³ & Ichio Shimada^{1,4}

Many drugs that target G-protein-coupled receptors (GPCRs) induce or inhibit their signal transduction with different strengths, which affect their therapeutic properties. However, the mechanism underlying the differences in the signalling levels is still not clear, although several structures of GPCRs complexed with ligands determined by X-ray crystallography are available. Here we utilized NMR to monitor the signals from the methionine residue at position 82 in neutral antagonist- and partial agonist-bound states of β_2 -adrenergic receptor (β_2 AR), which are correlated with the conformational changes of the transmembrane regions upon activation. We show that this residue exists in a conformational equilibrium between the inverse agonist-bound states and the full agonist-bound state, and the population of the latter reflects the signal transduction level in each ligand-bound state. These findings provide insights into the multi-level signalling of β_2 AR and other GPCRs, including the basal activity, and the mechanism of signal transduction mediated by GPCRs.

¹ Graduate School of Pharmaceutical Sciences, The University of Tokyo, Hongo 7-3-1, Bunkyo-ku, Tokyo 113-0033, Japan. ² Japan Biological Informatics Consortium (JBIC), Tokyo 135-0064, Japan. ³ Shionogi Co., Ltd., Discovery Research Laboratories, Osaka 561-0825, Japan. ⁴ Biomedical Information Research Center (BIRC), National Institute of Advanced Industrial Science and Technology (AIST), Aomi 2-41-6, Koto-ku, Tokyo 135-0064, Japan. Correspondence and requests for materials should be addressed to I.S. (email: shimada@iw-nmr.f.u-tokyo.ac.jp).

G-protein-coupled receptors (GPCRs) are one of the largest membrane protein families in eukaryotes¹, and more than 25% of modern drugs target GPCRs². These drugs bind to GPCRs, leading to the induction or inhibition of signal transduction mediated by G-proteins, β -arrestins and various other effectors via GPCRs. Each chemical ligand for a GPCR has a different level of ability to activate or inhibit its target, which is commonly referred to as efficacy, and the ligands are classified according to their efficacies, such as full agonists, partial agonists, neutral antagonists and inverse agonists^{3,4}. These differences in the efficacies significantly affect the therapeutic properties of the GPCR ligands. In the case of drugs that target β_2 -adrenergic receptor (β_2 AR), a full agonist offers a clinical advantage over a partial agonist in acute severe asthma, although full agonists are capable of causing more adverse effects⁵.

Structural analyses of β_2 AR complexed with various ligands are required to clarify the mechanism that determines the ligand efficacies. The crystal structures of β_2 AR have been solved in the forms bound to inverse agonists^{6–10}, a neutral antagonist¹⁰, a full agonist¹¹ and a full agonist with a G-protein¹² or a G-protein-mimicking nanobody¹³ (PDB accession codes: 3D4S, 2RH1, 3PDS, 3SN6, and 3P0G). In the structure of the form bound to both a full agonist and a G-protein, the cytoplasmic half of transmembrane 6 (TM6) shifted outward, in comparison with that in the inverse agonist-bound form, and the C-terminal helix of the G-protein was inserted into a cytoplasmic cavity. In addition, the ligand-dependent conformational changes of the solvent-exposed extracellular and intracellular regions were observed in biochemical studies with fluorescent labeling^{14–16}, chemical labeling¹⁷ and hydrogen–deuterium exchange techniques¹⁸, as well as solution NMR analyses using chemical modifications with ¹³CH₃ probes¹⁹. However, the structure of the β_2 AR TM region, which is directly involved in the conformational changes upon ligand binding, has not been examined in the neutral antagonist-bound and partial agonist-bound states. In addition, the crystal structures cannot fully explain the mechanism of the efficacies, including the basal activity¹⁰. Liu *et al.*²⁰ recently incorporated CF₃ probes, which can be observed with high sensitivity and selectivity, into β_2 AR and demonstrated that the ¹⁹F-NMR signals from the CF₃ probe at C265^{6,27} (superscripts indicate Ball-esteros–Weinstein numbering²¹) exhibited two components, which are referred to as I and A, and the population of A correlates with the efficacy of each ligand. I and A were structurally characterized by the PRE experiments, which suggested that C327^{7,54} is more exposed to solvent in I than in A, in an agonist-bound state²⁰.

Here we utilized NMR to clarify the conformational diversity of the TM region of β_2 AR in the inverse agonist-bound state, neutral antagonist-bound state, partial agonist-bound states and full agonist-bound state. Our NMR analyses revealed that the methionine residue at position 82 is in a conformational equilibrium between the inverse agonist-bound states and the full agonist-bound state, and the population of the latter reflects the signal transduction level in each ligand-bound state.

Results

Preparation and characterization of β_2 AR. The E122W/N187E/C265A mutant of β_2 AR (Gly2–Gly365) with an N-terminal FLAG-tag and a C-terminal decahistidine-tag, which exhibited agonist-dependent signalling activities almost identical to the wild type in previous studies^{14,22}, was expressed in a baculovirus–insect cell expression system. β_2 AR was solubilized by *n*-dodecyl- β -D-maltopyranoside (DDM), and purified by three chromatography steps, including ligand-affinity chromatography, to more than 95% purity, as judged from SDS–polyacrylamide gel electrophoresis (SDS–PAGE) analyses. The purified β_2 AR is in the formoterol-bound state, because formoterol was added during the elution from the ligand-affinity chromatography. Radioligand-binding assays with an excess amount of [³H]-dihydroalprenolol (DHA), which

Figure 1 | Analyses of ligand-dependent conformational changes in β_2 AR with fluorescent probes. (a) Schematic representation of the fluorescent assay⁸. A monobromobimane (mBBR) probe is introduced at C265^{6,27} of the β_2 AR without the C265A mutation (orange). After purification, β_2 AR is in the formoterol-bound state (brown). By the addition of an excess amount of alprenolol (green), formoterol (magenta) is replaced with alprenolol, resulting in β_2 AR in the alprenolol-bound state (blue). The receptor conformation shift from an active conformation to an inactive conformation was observed as the increase in the fluorescence intensity of mBBR, due to the change in the local environment. (b) Fluorescence spectra of mBBR-labeled β_2 AR, in the presence of formoterol (cyan), and after the addition of an excess amount of alprenolol (orange). The fluorescence intensities are normalized to the maximal fluorescence intensity in the alprenolol-bound state.

has a higher affinity for β_2 AR than formoterol^{23,24}, revealed that more than 80% of the purified β_2 AR retained the DHA-binding activity. We also confirmed that the purified β_2 AR exhibited ligand-dependent conformational changes, by experiments using a fluorescent probe introduced at C265^{6,27} (ref. 8) (Fig. 1a,b).

Methionine residues are frequently observed in TM3, TM5, and TM6 of GPCR, and these regions exhibit large conformational changes upon activation (Supplementary Fig. S1). β_2 AR possesses nine methionine residues in extracellular loop 1 (ECL1), TM1, TM2, TM4, TM5 and TM6 (Fig. 2 and Table 1), and M82^{2,53} (Supplementary Figs S2 and S3), M215^{5,54} and M279^{6,41} assume distinctly different conformations between the inverse agonist-bound and the full agonist/G-protein-bound crystal structures. Therefore, we utilized the methionine methyl groups to investigate the conformation of the TM region of β_2 AR in various ligand-bound states. Methionine methyl-selective ¹³C labeling in the baculovirus–insect cell expression system was accomplished by adding [methyl-¹³C] methionine to methionine-deficient medium. We confirmed that about 90% of the methionine methyl groups in thioredoxin, prepared by the same procedure for β_2 AR, were labeled with ¹³C and that the other types of amino-acid residues were not significantly labeled. ¹H-¹³C heteronuclear multiple quantum coherence (HMQC) spectra of the [methyl-¹³C-Met] β_2 AR in the formoterol-bound state were recorded, and those in the carazolol-bound state were recorded by adding an excess amount of carazolol.

Figure 2 | Distribution of the methionine residues in the overlaid crystal structures of β_2 AR. The crystal structure of β_2 AR with an inverse agonist, carazolol (PDB accession code: 2RH1)⁷, is shown in grey ribbons. Methionine side chains and carazolol are depicted by cyan and grey sticks, respectively. The crystal structure of β_2 AR with a full agonist, BI-167107, and a G-protein (PDB accession code: 3SN6)¹² is shown in violet ribbons. Methionine sidechains and BI-167107 are depicted by orange and violet sticks, respectively. These structures are overlaid at TM2, and are shown in a side view with the extracellular sides on the upper sides. ICL3s, which are either substituted with T4 lysozyme or not observed, are shown with dotted lines.

Degradation of β_2 AR did not occur during the NMR measurements, and the ligand-binding activity remaining after the NMR measurements was about 90% of that of freshly prepared β_2 AR (Supplementary Fig. S4a and b).

Spectra of the inverse agonist- and full agonist-bound forms. Signals that apparently correspond to the nine methionine residues were observed in the carazolol-bound state (Fig. 3a), suggesting that most of the methionine residues were observed, including those in the TM region. Several signals disappeared in the spectrum of the formoterol-bound state (Fig. 3b) compared with that in the carazolol-bound state (Fig. 3a).

To overcome the severe signal overlaps, we introduced mutations into the solvent- or lipid-exposed methionine residues of β_2 AR (M96^{2.67}, M98^{2.69}, M156^{4.48} and M171^{4.63}), assuming that these mutations would not affect the native folding of β_2 AR. Hereafter, we refer to these residues as 4Met. The HMQC spectra were significantly simplified by introducing the 4Met mutation, because four intense signals disappeared in both the carazolol- and formoterol-bound states (Fig. 3c,d). The chemical shifts and signal intensities of the remaining signals did not exhibit significant changes upon introducing the 4Met mutation in both the carazolol- and formoterol-bound states (Fig. 3a–d), suggesting that the folding of the 4Met mutant is similar to that of the wild type.

For the assignments of the resonances from the methionine in the TM region, we introduced a further mutation into the methionine residue of interest (Supplementary Fig. S5). For example, M82^{2.53} was assigned by introducing the M82V mutation into the 4Met mutant (Supplementary Fig. S5d). We confirmed that M82V retains the native folding in both the carazolol- and formoterol-bound states, by experiments using a fluorescent probe introduced at C265^{6.27} (Fig. 1b and Supplementary Fig. S6). In addition, the M82V mutation does not affect the affinity of the antagonist [³H] DHA to β_2 AR (Supplementary Fig. S7). In the carazolol-bound state, two signals were absent in the spectrum of the M82V mutant, revealing that both of these resonances are from M82^{2.53} (Fig. 3c,e). Hereafter, we refer to the downfield and upfield resonances from M82^{2.53} as M82^D and M82^U, respectively. In the formoterol-bound state, one signal was absent in the spectrum of the M82V mutant, revealing that this resonance is from M82^{2.53} (Fig. 3d,f). The chemical shifts of the resonance from M82^{2.53} in the formoterol-bound state were different from M82^D and M82^U in the carazolol-bound state (Fig. 4a). Hereafter, this resonance from M82^{2.53} in the full agonist formoterol-bound state is referred to as M82^A.

The resonances from M215^{5.54} and M279^{6.41} in the carazolol-bound state were also assigned using the 4Met-based mutants (Supplementary Fig. S5e,f). The spectra of the mutants for M215^{5.54} and M279^{6.41} in the formoterol-bound state were not significantly different from those without these mutations, suggesting that the resonances from M215^{5.54} and M279^{6.41} were not observed in the formoterol-bound state (Fig. 4a).

M82 in the states bound with antagonist and partial agonists.

To investigate the structures of the TM region in the neutral antagonist-bound and partial agonist-bound states, the HMQC spectra of the 4Met mutant labeled with methyl-¹³C-Met were recorded in the state bound with the neutral antagonist, alprenolol, and in those bound with the partial agonists, tulobuterol and clenbuterol (Fig. 4b,c). Alprenolol does not alter the basal activity of β_2 AR^{16,19}. Clenbuterol reportedly has higher efficacy than tulobuterol²⁴ (Supplementary Table S1). The tulobuterol- and clenbuterol-bound states were achieved by extensive washing with these ligands on cobalt-affinity resin after the ligand-affinity purification steps. The alprenolol-bound state was attained by adding an excess amount of alprenolol over clenbuterol. As a result, in the alprenolol-bound state, a major and a minor resonance that slightly shifted from M82^U and M82^D, respectively, were observed (Fig. 4b,c). In both the tulobuterol- and clenbuterol-bound states, a signal was observed at a chemical shift between M82^U and M82^A, and the chemical shifts in the tulobuterol-bound state were closer to those of M82^U (Fig. 4b,c).

To examine whether the resonances from M82^{2.53} in the ligand-bound states undergo conformational exchange, we also recorded the spectra at a lower temperature, 283 K (Fig. 4d and Supplementary Fig. S8). As a result, the resonances from M82^{2.53} in the tulobuterol- and clenbuterol-bound states significantly shifted away from M82^U, and the M82^A resonance in the formoterol-bound state slightly shifted away from M82^U at 283 K (Fig. 4d and Supplementary Fig. S8a–c), whereas the resonances from the methyl groups of tulobuterol and clenbuterol did not shift (Supplementary Fig. S8d,e). In the spectra of β_2 AR with lower concentrations of clenbuterol and tulobuterol, the signals were observed at the same chemical shifts as those at higher ligand concentrations (Supplementary Fig. S9), suggesting that the NMR signals are not significantly affected by the exchange between the free and bound states or non-specific effect of the ligands, because β_2 AR is only in the ligand-bound state under the present solution conditions. This is consistent with the estimation of the bound population of β_2 AR by the ligand concentration of the NMR samples and the reported affinities of the ligands (Supplementary Table S1).

Table 1 Summary of the differences in β_2 AR methionine resonances in the states with various efficacies.									
	M36	M40	M82	M96	M98	M156	M171	M215	M279
<i>Position in the β_2AR structure</i>									
Structural element*	TM1	TM1	TM2	TM2	ECL1	TM4	TM4	TM5	TM6
Extracellular half (E) or intracellular half (I)	E	E	E	E	E	I	E	I	I
Large conformational change upon activation	No	No	Yes	No	No	No	No	Yes	Yes
<i>Number of observed resonances in each ligand-bound state</i>									
Carazolol	1	0	2	1	1	1	1	1	1
Alprenolol	1	0	2	1	1	1	1	1	1
Tulobuterol	1	0	1	1	1	1	1	1	1
Clenbuterol	1	0	1	1	1	1	1	1	1
Formoterol	1	0	1	1	1	1	1	0	0
<i>Efficacy-dependent changes</i>									
In chemical shifts	No‡	—	Yes	No‡	No‡	No‡	No‡	Yes	Yes
In signal intensities†	No	—	Yes§	No	No	No	No	Yes	Yes

*TM and ECL stand for transmembrane helix and extracellular loop, respectively.

†The signal intensities were normalized by dividing the observed intensities with the concentrations of β_2 AR, estimated from the SDS-PAGE, and the numbers of scans.

‡Normalized chemical shift differences were < 0.1 p.p.m.

§In a complex manner, depending on both the populations and the exchange rates between the M82^A, M82^U, and M82^D states.

||Carazolol > alprenolol > tulobuterol > clenbuterol.

Figure 3 | ^1H - ^{13}C SOFAST-HMQC spectra of [methyl- ^{13}C -Met] β_2 AR and their assignments. (a,b) ^1H - ^{13}C SOFAST-HMQC spectra of [methyl- ^{13}C -Met] β_2 AR in the carazolol-bound state (a) and in the formoterol-bound state (b). (c,d) ^1H - ^{13}C SOFAST-HMQC spectra of the [methyl- ^{13}C -Met] β_2 AR 4Met mutant in the carazolol-bound state (c) and in the formoterol-bound state (d). (e,f) ^1H - ^{13}C SOFAST-HMQC spectra of the [methyl- ^{13}C -Met] β_2 AR 4Met/M82V mutant in the carazolol-bound state (e) and in the formoterol-bound state (f). The regions with methionine chemical shifts are shown, and the assigned resonances are indicated. The resonances from M40 in the carazolol-bound state, and M40, M215 and M279 in the formoterol-bound state were not observed. Resonances indicated with single asterisk are derived from minor impurity proteins from insect cell membranes, but not from β_2 AR. Double asterisks are t_1 noises derived from the intense DDM signal with an ^1H chemical shift of 1.6–1.7 p.p.m.

Signals from the residues except for M82. The resonances from M215, which is in the intracellular side of TM5, in the states with carazolol, alprenolol, tulobuterol, clenbuterol and formoterol are shown in Fig. 5a,b. M215 exhibited single resonance in the carazolol-, alprenolol-, tulobuterol- and clenbuterol-bound states (Fig. 5a,b). The chemical shifts in the alprenolol- and tulobuterol-bound states were between those in the carazolol- and clenbuterol-bound states, and the chemical shifts in the alprenolol-bound state were closer to those in the carazolol-bound state. The intensities

were in the following order: carazolol-bound state > alprenolol-bound state > tulobuterol-bound state > clenbuterol-bound state and the resonances from M215 were not observed in the formoterol-bound state (Table 1). As the temperature was lowered from 298 K to 283 K, the M215 resonances in the carazolol- and alprenolol-bound states shifted towards that in the carazolol-bound state (Supplementary Fig. S10). The chemical shifts and intensities of the resonances from M279, which is in the intracellular side of TM6, also exhibited similar bound ligand-dependent changes (Fig. 5c).

Figure 4 | The difference in $\beta_2\text{AR}$ M82^{5.53} resonances in the states with various efficacies. (a) Overlay of the ^1H - ^{13}C SOFAST-HMQC spectra of [methyl- ^{13}C -Met] $\beta_2\text{AR}$ /4Met at 298 K in the carazolol-bound state (black) and the formoterol-bound state (red). (b) ^1H - ^{13}C SOFAST-HMQC spectra of [α,β,β - $^2\text{H}_3$, methyl- ^{13}C -Met] $\beta_2\text{AR}$ /4Met at 298 K in the carazolol-bound (black), alprenolol-bound (cyan), tulobuterol-bound (green), clenbuterol-bound (violet) and formoterol-bound (red) states. Only the regions with M82 resonances are shown. (c) Overlay of the spectra shown in panel (b), with the same colors. The centers of the resonances from M82 are indicated with dots. (d) ^1H - ^{13}C SOFAST-HMQC spectra of [α,β,β - $^2\text{H}_3$, methyl- ^{13}C -Met] $\beta_2\text{AR}$ /4Met at 283 K, with the same colors as in panel (b). In panels a–d, the assigned resonances are indicated with the names of the bound ligands in parentheses (a,c). M82 resonances are indicated with the superscripts used in the main text. Resonances indicated with single asterisk are derived from impurities. Double asterisks are t_1 noises derived from the intense DDM signal with an ^1H chemical shift of 1.6–1.7 p.p.m.

The HMQC spectra of the $\beta_2\text{AR}$ without the 4Met mutation were also recorded in the state bound with alprenolol, tulobuterol and clenbuterol, as well as carazolol and formoterol (Supplementary Fig. S11). As a result, the chemical shift changes observed for the $\beta_2\text{AR}$ without the 4Met mutation were almost identical to those for the 4Met mutant, although the M82 resonances partially overlapped with the resonances from M96 or M98. Therefore, we can rule out the effect of the 4Met mutation on the efficacy in each ligand-bound state.

The differences in the other methionine resonances in each ligand-bound state are summarized in Fig. 6 and Table 1. The resonances from M36, M96/M98, M156 and M171 exhibited only small chemical shift differences in each ligand-bound state (Fig. 6 and Table 1).

Discussion

Different spectrum patterns from the M82^{5.53} methyl group are observed, depending on the efficacy of the bound ligand:

the resonances of M82^U and M82^D in the inverse agonist-bound state, two resonances with slightly different chemical shifts from M82^U and M82^D in the neutral antagonist-bound state, one resonance with a chemical shift between M82^U and M82^A in the partial agonist-bound states and the resonance of M82^A in the full agonist-bound state (Fig. 4b–d).

Based on the comparison between the $\beta_2\text{AR}$ crystal structures in the forms bound with an inverse agonist and with both a full agonist and a G-protein, the following structural mechanism for GPCR activation was proposed¹³: full agonists induce a conformational change of S207^{5.46} and a subsequent rearrangement of the interactions between the TM helices in the middle of the TM region; the inward shifts of TM5 and TM7 at P211^{5.50} and N318^{7.45}, respectively, and the axial shifts of TM3 and TM6 at I121^{3.40} and F282^{6.44}, respectively, resulting in a large outward movement of the cytoplasmic half of TM6 (Supplementary Fig. S2). The M82^{5.53} side chain also exhibits a dramatic conformational change upon activation, and this conformational change strongly correlates with the rearrangement

Figure 5 | The difference in β_2 AR M215^{5.54} or M279^{6.41} resonances in the states with various efficacies. (a) ^1H - ^{13}C SOFAST-HMQC spectra of $[\alpha, \beta, \beta\text{-}^2\text{H}_3\text{-}, \text{methyl-}^{13}\text{C-Met}] \beta_2\text{AR}/4\text{Met}$ at 298 K in the carazolol-bound (black), alprenolol-bound (cyan), tulobuterol-bound (green), clenbuterol-bound (violet) and formoterol-bound (red) states. Only regions with M36 and M215 resonances are shown. (b) Overlay of the spectra shown in panel a, except for the formoterol-bound state, with the same colors. In panel b, only the regions with M215 resonances are shown. The centers of the resonances from M215 are indicated with dots. (c) Overlay of the regions with M279 resonances of the ^1H - ^{13}C SOFAST-HMQC spectra of $[\alpha, \beta, \beta\text{-}^2\text{H}_3\text{-}, \text{methyl-}^{13}\text{C-Met}] \beta_2\text{AR}/4\text{Met}$ at 298 K in the carazolol-bound (black), alprenolol-bound (cyan), tulobuterol-bound (green) and clenbuterol-bound (violet) states. The centers of the resonances from M279 are indicated with dots. The line shapes of the M279 resonances are distorted due to the overlaps with the t_1 noises derived from the intense DDM signal with an ^1H chemical shift of 1.6–1.7 p.p.m.

Figure 6 | Normalized chemical shift differences of the methionine methyl resonances between the carazolol- and formoterol-bound states. Normalized chemical shift differences, $\Delta\delta$, were calculated by the equation $\Delta\delta = \{(\Delta\delta_{\text{H}})^2 + (\Delta\delta_{\text{C}}/3.5)^2\}^{0.5}$. The normalization factor (3.5) is the ratio of the s.d. of the methionine methyl ^1H and ^{13}C chemical shifts, deposited in the Biological Magnetic Resonance Data Bank (<http://www.bmrb.wisc.edu/>). The error values were calculated by the formula $\{(\Delta\delta_{\text{H}}/R_{\text{H}} + \Delta\delta_{\text{C}}/R_{\text{C}})/(3.5)^2\}/\Delta\delta$, where R_{H} and R_{C} are the digital resolutions in p.p.m. in the ^1H and ^{13}C dimensions, respectively. The number of replicates is greater than two. For M82, both of the $\Delta\delta$ s between M82^U and M82^A (M82^{U/A}), and M82^D and M82^A (M82^{D/A}) were calculated. For M215 and M279, we could not calculate the $\Delta\delta$ s between the carazolol- and formoterol-bound states, because these resonances were not observed in the formoterol-bound state, although $\Delta\delta$ s between the carazolol- and clenbuterol-bound states, which should be smaller than those between the carazolol- and formoterol-bound states, were >0.1 p.p.m.

of the interactions between I121^{3.40} and F282^{6.44} (Supplementary Fig. S3), via the inward shift of TM7 at Y316^{7.43} and S319^{7.46} and the axial shift of TM3 at C116^{3.35} (Supplementary Fig. S2). Therefore,

the side-chain conformation of M82^{2.53} would be sensitive to the activation state of β_2 AR. On the other hand, M82^{2.53} is 5–8 Å away from the conserved β -OH groups of the β_2 AR ligands, and is not directly involved in the ligand binding. Therefore, the resonances from M82^{2.53} would be less affected by the direct interactions with ligands. This is supported by further observation that the affinity of the antagonist [^3H] DHA for the 4Met/M82V mutant was almost identical to that for the 4Met mutant (Supplementary Fig. S7).

The ^{13}C and ^1H chemical shifts of the methionine methyl signals are reportedly affected by its side-chain conformation and the local environments, including the ring current effects from the neighbouring aromatic rings, respectively^{25–27}. Based upon the crystal structures of β_2 AR, we propose that the M82^U and M82^D signals correspond to the inactive states that cannot directly activate G-proteins, and the M82^A signal corresponds to the active state that can interact with G-proteins (Supplementary Discussion). Therefore, the differences between the conformations corresponding to M82^U and M82^D are found in a limited region close to the ligand-binding site. In contrast, the differences between the conformations corresponding to M82^{U/D} and M82^A are found in the TM region. Hereafter, we refer to these conformations corresponding to M82^U, M82^D and M82^A as the M82^U conformation, the M82^D conformation and the M82^A conformation, respectively.

Previous comprehensive analyses of efficacies in various ligands revealed that the efficacies increase in the following order²⁴: an inverse agonist, carazolol; a neutral antagonist, oxprenolol, which is an analogue of alprenolol; a weak partial agonist tulobuterol; a partial agonist, clenbuterol; and a full agonist, formoterol (Supplementary Table S1). In the neutral antagonist-bound and partial agonist-bound states, the M82^{2.53} resonances exhibited chemical shifts between M82^U and M82^A in an efficacy-dependent manner (Fig. 4c). The resonances from M82^{2.53} in the partial agonist-bound states shifted towards M82^A as the temperature was lowered from 298 K to 283 K (Supplementary Fig. S8a,b). The temperature-dependent shifts, together with the chemical shifts in

an efficacy-dependent manner, suggest that β_2 AR exists in equilibrium between the $M82^U$ and $M82^A$ conformations in the partial agonist-bound states, with faster exchange rates than the chemical shift difference. The observation of two resonances from $M82^{2.53}$ in the carazolol- and alprenolol-bound states suggests that β_2 AR exists in equilibrium between the $M82^D$ and $M82^U$ conformations in the inverse agonist- and neutral antagonist-bound states, with slower exchange rates than the chemical shift difference. The two resonances from $M82^{2.53}$ in the alprenolol-bound state were closer to $M82^A$ than those in the carazolol-bound state, suggesting that the minor population of the $M82^A$ conformation, in equilibrium with the $M82^U$ conformation, would also exist in this state, as supported by the simulation of $M82^{2.53}$ resonances (Supplementary Discussion). The incomplete linearity of the efficacy-dependent chemical shift change might be derived from another equilibrium within the $M82^A$ conformation.

Similar phenomena were also observed for the M215 and M279 resonances. The M215 and M279 resonances exhibited the chemical shifts and intensities in an efficacy-dependent manner (Fig. 5 and Table 1), and these resonances shifted towards those in the carazolol-bound state at lower temperature (Supplementary Fig. S10a and b). The simulations of these resonances, with the same parameter as that of the M82 resonances, were in good agreement with the observed spectra (Supplementary Discussion). Therefore, the efficacy-dependent conformational equilibrium between the $M82^D/U$ and $M82^A$ conformations observed for $M82^{2.53}$ accompanies large conformational changes on TM5 and TM6.

Based on the above structural interpretation of the resonances from M82, we propose the following signal regulation mechanism. In the full agonist formoterol-bound state, most of the β_2 AR molecules assume the active conformation (Fig. 7a). In the partial agonist tulobuterol- and clenbuterol-bound states, β_2 AR exists in an equilibrium between the inactive and active conformations (Fig. 7b), and the populations of the two conformations determine the efficacies. This is in good agreement with the significant, but reduced, efficacy for tulobuterol and clenbuterol²⁴. In the neutral antagonist alprenolol-bound state, β_2 AR exists in equilibrium between two major inactive conformations, which are different only in the region close to the ligand-binding site, and one minor active conformation (Fig. 7c). The weak basal activity is due to the existence of the minor $M82^A$ conformation. In the inverse agonist-bound state, β_2 AR exists in equilibrium between the two locally different inactive conformations (Fig. 7d). Considering that the basal activity partly remained even in the carazolol-bound state^{16,24}, there may be a minor population of the $M82^A$ conformation in this state, in an equilibrium with one of the inactive conformations.

Two mechanisms have been proposed for the partial efficacies in the partial agonist-bound states: the equilibrium between the active and inactive states, and the distinct conformation of the partial agonist-bound state from those of both the active and inactive states³, although there have been no experimental evidence for them. The chemical shifts of the $M82^{2.53}$ resonances in the efficacy-dependent and the temperature-dependent manner in the partial agonist-bound states suggest the equilibrium between the active and inactive states.

The $M82^D$ resonance was observed only in the inverse agonist- and neutral antagonist-bound states, and the intensity of the $M82^D$ resonance is higher in the inverse agonist-bound state than in the neutral antagonist state. In addition, the ^{13}C chemical shifts of $M82^U$ and $M82^D$ suggest that the $M82^U$ conformation flexibly adopts both the *trans* and *gauche* conformations, whereas the $M82^D$ conformation mainly adopts the *trans* conformation (Supplementary Discussion); therefore, the $M82^D$ conformation may be more rigid than the $M82^U$ conformation. It is thus tempting to speculate that the $M82^D$ conformation is more refractory to shifting to the activated state than the $M82^U$ conformation, and the higher

Figure 7 | A proposed mechanism for the differences in the efficacy of β_2 AR for different ligands. β_2 AR adopts three conformations with different $M82^{2.53}$ environments; the $M82^A$ conformation induces signalling, whereas the $M82^U$ and $M82^D$ conformations do not. $M82^U$ and $M82^A$ conformations are largely different on TM5 and TM6, whereas the differences between $M82^D$ and $M82^U$ conformations are localized in the region close to the ligand-binding site. **(a)** In the full agonist formoterol-bound state, β_2 AR adopts mostly the $M82^A$ conformation, exhibiting almost full efficacy of β_2 AR. **(b)** In the partial agonist clenbuterol- and tulobuterol-bound states, β_2 AR exists in equilibrium between the $M82^A$ and $M82^U$ conformations, exhibiting the significant signaling with reduced efficacies. In the tulobuterol-bound state, where the efficacy is lower than that of the clenbuterol-bound state, the populations of the $M82^U$ conformation are larger. **(c)** In the neutral antagonist alprenolol-bound state, β_2 AR adopts mostly the $M82^U$ and $M82^D$ conformations, in equilibrium with a small population with the $M82^A$ conformation. The presence of the small population with the $M82^A$ conformation accounts for the basal activity of β_2 AR. **(d)** In the inverse agonist carazolol-bound state, β_2 AR exists in equilibrium between the $M82^U$ and $M82^D$ conformations, exhibiting the inhibition of basal activities described in panel c.

population of the $M82^D$ conformation in the inverse agonist-bound state causes the inhibition of the basal activity.

The resonances from M215^{5,54} and M279^{6,41}, which are located on the cytoplasmic side of the TM region, were not observed in the formoterol-bound state, suggesting that these signals were broadened due to the conformational exchange between the multiple

conformations in the formoterol-bound state. The multiple conformations on the cytoplasmic side of the TM region in the full agonist-bound state may be effective for interacting with various effectors in the conformational selection manners²⁰. A number of β_2 AR ligands have been shown to impart differing degrees of signalling in G-protein and arrestin pathways, a phenomenon called 'functional selectivity' or 'biased signalling'^{20,28–32}. The biased signalling is important for both understanding the functions of GPCRs and drug development, and it is quite interesting to investigate the conformations of β_2 AR in the biased ligand-bound states. Although biased signalling was not reported for the ligands chosen in this study²⁰, the biased signalling may be due to the diversity of the conformational dynamics in the cytoplasmic side of the TM region in each ligand-bound state.

The conformational differences between the crystal structures of β_2 AR were also basically observed in those of adenosine A_{2A} receptor and rhodopsin^{33–35}. In addition, methionine residues are highly abundant in TM3, TM5 and TM6, as described above (Supplementary Fig. S1), and can be observed without any chemical modification. Therefore, the methionine ^1H - ^{13}C resonances, including Met^{2.53}, are broadly applicable for the analyses of the bound ligand efficacy-dependent conformational differences in various GPCRs.

Methods

Reagents and buffers. All reagents were from Nacalai Tesque, unless otherwise noted. The [α,β , $^2\text{H}_3$, methyl- ^{13}C] methionine was prepared by the enzymatic deuteration of [methyl- ^{13}C] methionine (ISOTEC or Cambridge Isotope Laboratories) with *Escherichia coli* cystathionine- γ -synthase, as previously described³⁶. Alprenolol-cysteamine (AlpC) was synthesized as previously described²². Affi-gel/AlpC was prepared by coupling 5 mg ml^{-1} AlpC solution with Affi-gel10 (Bio-Rad) in a dimethyl sulfoxide (DMSO, Dojindo) solution, according to the manufacturer's instructions. Carazolol (Wako Chemicals) and formoterol (Sigma) were solubilized at 100 mM in DMSO- d_6 (ISOTEC), and diluted with buffers. Tulobuterol (Wako Chemicals) was solubilized at 400 mM in methanol- d_4 (ISOTEC), and diluted with buffers. Alprenolol (Sigma) and clenbuterol (Wako Chemicals) were solubilized at 100 mM in D_2O (Cambridge Isotope Laboratories), and diluted with buffers.

Generation of β_2 AR recombinant baculovirus. The complementary DNA fragment encoding human β_2 AR (Gly2–Gly365), with an N-terminal FLAG-tag (DYKDDDDA) and a C-terminal decahistidine-tag was amplified by PCR and cloned into the pFastBac1 vector (Invitrogen) via the *Bam*HI-*Xba*I sites. The sequence encoding the gp64 signal sequence was amplified from the pBAC-6 vector (Novagen), and placed immediately 5' to the FLAG-tag. Mutations were introduced by either a QuikChange site-directed mutagenesis kit or a QuikChange multi site-directed mutagenesis kit (Stratagene). E122W, N187E and C265A mutations were introduced in all constructs, unless otherwise stated.

Sf9 cells (Invitrogen) were routinely maintained at 27°C in Grace's supplemented medium (GIBCO) containing 10% fetal bovine serum (Biowest), 0.1% Pluronic F-68 (GIBCO), 50 international units per ml penicillin, $50\text{ }\mu\text{g ml}^{-1}$ streptomycin and $0.125\text{ }\mu\text{g ml}^{-1}$ amphotericin B. Recombinant baculoviruses were generated and amplified with the Bac-to-Bac system (Invitrogen), according to the manufacturer's instructions.

Expression and purification of β_2 AR. The expresSF+ cells (SF+ cells, Protein Sciences) were routinely maintained at 27°C in 100 ml Sf-900 II serum-free medium (GIBCO), with 50 international units per ml penicillin, $50\text{ }\mu\text{g ml}^{-1}$ streptomycin and $0.125\text{ }\mu\text{g ml}^{-1}$ amphotericin B, in a 250 ml Erlenmeyer flask (Corning) on an orbital shaker (130 r.p.m.). For the expression of [methyl- ^{13}C -Met] β_2 AR, SF+ cells in Sf-900 II medium were centrifuged at 200g, and resuspended in methionine-depleted ESF921 medium (Expression Systems), at about 2×10^6 cells per ml. For the expression of non-labeled β_2 AR, Sf-900 II medium was utilized instead of the methionine-depleted ESF921 medium. The cells were inoculated with the high-titer virus stock (40 ml per 1 l of cells). After 16 h post infection, 200 mg l^{-1} [methyl- ^{13}C] methionine was added. Cells were harvested 48 h post infection by centrifugation at 1,000g, and the resulting cell pellets were stored at -80°C . For the expression of [α,β , $^2\text{H}_3$, methyl- ^{13}C -Met] β_2 AR, 200 mg l^{-1} [α,β , $^2\text{H}_3$, methyl- ^{13}C] methionine was added instead of [methyl- ^{13}C] methionine.

All of the following procedures were either performed on ice or in the cold room (4°C). The cell pellet from 0.8 l of cell culture was re-suspended in 100 ml buffer A (50 mM Tris, pH 8.0, 100 mM NaCl, 1 mM EDTA, 1 mM 4-(2-aminoethyl) benzenesulfonyl fluoride hydrochloride (AEBSEF), $10\text{ }\mu\text{M}$ leupeptin hemisulfate (Peptide Institute), $14\text{ }\mu\text{M}$ E-64 (Peptide Institute),

$0.3\text{ }\mu\text{M}$ aprotinin (Wako Chemicals)). The cells were disrupted by nitrogen cavitation (Parr Bomb) under 600 p.s.i. for 30 min. The cell lysate was centrifuged at 800g for 10 min, and the resulting supernatant was centrifuged at 100,000g for 60 min. The membrane pellet was suspended in buffer B (20 mM HEPES, pH 7.2, 150 mM NaCl, 15% (v/v) glycerol, $100\text{ }\mu\text{M}$ AEBSEF, $10\text{ }\mu\text{M}$ leupeptin hemisulfate, $14\text{ }\mu\text{M}$ E-64) and was stored at -80°C .

The membranes obtained from 0.8 l of cell culture were solubilized in 40 ml of buffer B, supplemented with 1% *n*-dodecyl- β -D-maltopyranoside (DDM, Dojindo) for 4 h, and were then centrifuged at 100,000g for 30 min. The supernatant was batch incubated overnight with 1 ml of TALON metal affinity resin (Clontech). The resin was washed with 30 ml of buffer B, supplemented with 0.1% DDM and 20 mM imidazole. The protein was eluted with 8 ml of buffer B, supplemented with 0.1% DDM and 200 mM imidazole.

For the ligand-affinity chromatography, the eluate from the TALON affinity resin was batch incubated for 4 h with 0.5 ml of Affi-gel/AlpC. The resin was washed with 10 ml of buffer B, and supplemented with 0.1% DDM. The protein was eluted overnight by a batch incubation of the resin with 5 ml of buffer B, supplemented with 0.1% DDM and 1 mM formoterol.

For the concentration and the ligand exchange of β_2 AR, a second TALON affinity step was performed after the ligand-affinity chromatography. The eluate from the ligand-affinity chromatography was batch incubated for 1 h with 0.5 ml of TALON resin. The resin was washed with 5 ml of buffer B, supplemented with 0.1% DDM and $100\text{ }\mu\text{M}$ formoterol. The ligand exchange from formoterol to clenbuterol or tulobuterol was accomplished by further washing of the resin for about 3 h, with 50 ml of buffer B, supplemented with 0.1% DDM and 1 mM ligands (clenbuterol or tulobuterol). The protein was eluted with 1 ml of buffer B, supplemented with 0.08% DDM, 200 mM imidazole and the ligands ($100\text{ }\mu\text{M}$ formoterol, 1 mM clenbuterol or 1 mM tulobuterol).

The eluate from the second TALON affinity step was concentrated using a centrifugal filter device (AmiconUltra-4, 30 kDa molecular weight cutoff, Millipore), while simultaneously exchanging the buffer to buffer C (20 mM sodium phosphate, pH 7.1, $\text{H}_2\text{O}/\text{D}_2\text{O} = 1/99$), supplemented with the ligands ($100\text{ }\mu\text{M}$ formoterol, 1 mM clenbuterol or 1 mM tulobuterol). In total, 50–400 μg of β_2 AR and its mutants were obtained per 0.8 l of insect cell culture.

NMR experiments. All of the spectra were recorded with a Bruker Avance 800 spectrometer equipped with a cryogenic probe, and were processed by Topspin 2.1 (Bruker).

The assignment of the methionine methyl ^1H - ^{13}C resonances of β_2 AR was accomplished by the following procedure. ^1H - ^{13}C SOFAST-HMQC spectra³⁷ and ^1H - ^{13}C HMQC spectra with echo/anti-echo gradient coherence selections³⁸ were recorded for 5–40 μM [methyl- ^{13}C -Met] β_2 AR and its mutants in buffer C, supplemented with $100\text{ }\mu\text{M}$ formoterol at 298 K. After the NMR experiments, carazolol was added to a final concentration of $500\text{ }\mu\text{M}$, and ^1H - ^{13}C SOFAST-HMQC spectra and ^1H - ^{13}C HMQC spectra with echo/anti-echo gradient coherence selections were recorded at 298 K, for the assignment of the methionine methyl ^1H - ^{13}C resonances in the carazolol-bound states. ^1H - ^{13}C HMQC spectra with echo/anti-echo gradient coherence selections were utilized to discriminate the methionine resonances from the t_1 noises derived from the intense DDM signals in the ^1H - ^{13}C SOFAST-HMQC spectra.

The structures of β_2 AR in the various ligand-bound states were investigated by the following procedure. ^1H - ^{13}C SOFAST-HMQC spectra were recorded for $20\text{ }\mu\text{M}$ [α,β , $^2\text{H}_3$, methyl- ^{13}C -Met] β_2 AR 4Met mutant and $40\text{ }\mu\text{M}$ [methyl- ^{13}C -Met] β_2 AR in buffer C, supplemented with ligands ($100\text{ }\mu\text{M}$ formoterol, 1 mM clenbuterol or 1 mM tulobuterol) at 283 K and 298 K. After the NMR experiments in the formoterol- and clenbuterol-bound states, carazolol and alprenolol were added to final concentrations of $500\text{ }\mu\text{M}$ and 1 mM, respectively, and ^1H - ^{13}C SOFAST-HMQC spectra were recorded at 283 K and 298 K.

^1H - ^{13}C SOFAST-HMQC spectra were recorded by excitation with a 4-ms PC9 120 degree pulse³⁹ and the inversion of a 2-ms Q3 180 degree pulse⁴⁰. For all of the spectra, the spectral widths were set to 12,800 Hz and 4,800 Hz for the ^1H and ^{13}C dimensions, respectively, and the inter-scan delays were set to 1 s. For the spectra recorded at 298 K in Supplementary Figs S5e–h, $1,024\times 128$ complex points were recorded, and 256 scans/FID gave rise to an acquisition time of 10 h for each spectrum. For the other spectra recorded at 298 K, $1,024\times 256$ complex points were recorded, and 128 scans/FID gave rise to an acquisition time of 10 h for each spectrum. For the spectra recorded at 283 K, $1,024\times 192$ complex points were recorded and 256 scans/FID gave rise to an acquisition time of 15 h for each spectrum. All the spectra were referenced with 3-(trimethylsilyl)-1-propanesulfonic acid sodium salt in both ^1H and ^{13}C dimensions.

References

1. Lagerström, M. C. & Schiöth, H. B. Structural diversity of G protein-coupled receptors and significance for drug discovery. *Nat. Rev. Drug Discov.* **7**, 339–57 (2008).
2. Overington, J. P., Al-Lazikani, B. & Hopkins, A. L. How many drug targets are there? *Nat. Rev. Drug Discov.* **5**, 993–6 (2006).
3. Kobilka, B. K. & Deupi, X. Conformational complexity of G-protein-coupled receptors. *Trends Pharmacol. Sci.* **28**, 397–406 (2007).

4. Rosenbaum, D. M., Rasmussen, S. G. & Kobilka, B. K. The structure and function of G-protein-coupled receptors. *Nature* **459**, 356–63 (2009).
5. Hanania, N. A., Dickey, B. F. & Bond, R. A. Clinical implications of the intrinsic efficacy of β -adrenoceptor drugs in asthma: full, partial and inverse agonism. *Curr. Opin. Pulm. Med.* **16**, 1–5 (2010).
6. Rasmussen, S. G. *et al.* Crystal structure of the human β_2 adrenergic G-protein-coupled receptor. *Nature* **450**, 383–7 (2007).
7. Cherezov, V. *et al.* High-resolution crystal structure of an engineered human β_2 -adrenergic G protein-coupled receptor. *Science* **318**, 1258–65 (2007).
8. Rosenbaum, D. M. *et al.* GPCR engineering yields high-resolution structural insights into β_2 -adrenergic receptor function. *Science* **318**, 1266–73 (2007).
9. Hanson, M. A. *et al.* A specific cholesterol binding site is established by the 2.8 Å structure of the human β_2 -adrenergic receptor. *Structure* **16**, 897–905 (2008).
10. Wacker, D. *et al.* Conserved binding mode of human β_2 adrenergic receptor inverse agonists and antagonist revealed by X-ray crystallography. *J. Am. Chem. Soc.* **132**, 11443–5 (2010).
11. Rosenbaum, D. M. *et al.* Structure and function of an irreversible agonist- β_2 adrenoceptor complex. *Nature* **469**, 236–40 (2011).
12. Rasmussen, S. G. *et al.* Crystal structure of the β_2 adrenergic receptor-Gs protein complex. *Nature* **477**, 549–55 (2011).
13. Rasmussen, S. G. *et al.* Structure of a nanobody-stabilized active state of the β_2 adrenoceptor. *Nature* **469**, 175–80 (2011).
14. Gether, U. *et al.* Agonists induce conformational changes in transmembrane domains III and VI of the β_2 adrenoceptor. *EMBO J.* **16**, 6737–47 (1997).
15. Yao, X. *et al.* Coupling ligand structure to specific conformational switches in the β_2 -adrenoceptor. *Nat. Chem. Biol.* **2**, 417–22 (2006).
16. Yao, X. J. *et al.* The effect of ligand efficacy on the formation and stability of a GPCR-G protein complex. *Proc. Natl Acad. Sci. USA* **106**, 9501–6 (2009).
17. Kahsai, A. W. *et al.* Multiple ligand-specific conformations of the β_2 -adrenergic receptor. *Nat. Chem. Biol.* **7**, 692–700 (2011).
18. West, G. M. *et al.* Ligand-dependent perturbation of the conformational ensemble for the GPCR β_2 adrenergic receptor revealed by HDX. *Structure* **19**, 1424–32 (2011).
19. Bokoch, M. P. *et al.* Ligand-specific regulation of the extracellular surface of a G-protein-coupled receptor. *Nature* **463**, 108–12 (2010).
20. Liu, J. J., Horst, R., Katritch, V., Stevens, R. C. & Wüthrich, K. Biased signaling pathways in β_2 -adrenergic receptor characterized by ^{19}F -NMR. *Science* **335**, 1106–1110 (2012).
21. Ballesteros, J. A. & Weinstein, H. Integrated methods for the construction of three-dimensional models and computational probing of structure-function relations in G-protein coupled receptors. *Methods Neurosci.* **25**, 366–428 (1995).
22. Roth, C. B., Hanson, M. A. & Stevens, R. C. Stabilization of the human β_2 -adrenergic receptor TM4-TM3-TM5 helix interface by mutagenesis of Glu122^{3,41}, a critical residue in GPCR structure. *J. Mol. Biol.* **376**, 1305–19 (2008).
23. Baker, J. G. The selectivity of β -adrenoceptor antagonists at the human β_1 , β_2 and β_3 adrenoceptors. *Br. J. Pharmacol.* **144**, 317–22 (2005).
24. Baker, J. G. The selectivity of β -adrenoceptor agonists at human β_1 -, β_2 - and β_3 -adrenoceptors. *Br. J. Pharmacol.* **160**, 1048–61 (2010).
25. London, R. E., Wingad, B. D. & Mueller, G. A. Dependence of amino acid side chain ^{13}C shifts on dihedral angle: application to conformational analysis. *J. Am. Chem. Soc.* **130**, 11097–105 (2008).
26. Butterfoss, G. L. *et al.* Conformational dependence of ^{13}C shielding and coupling constants for methionine methyl groups. *J. Biomol. NMR* **48**, 31–47 (2010).
27. Perkins, S. J. & Wüthrich, K. Ring current effects in the conformation dependent NMR chemical shifts of aliphatic protons in the basic pancreatic trypsin inhibitor. *Biochim. Biophys. Acta* **576**, 409–23 (1979).
28. Rajagopal, K., Lefkowitz, R. J. & Rockman, H. A. When 7 transmembrane receptors are not G protein-coupled receptors. *J. Clin. Invest.* **115**, 2971–4 (2005).
29. Shenoy, S. K. & Lefkowitz, R. J. β -arrestin-mediated receptor trafficking and signal transduction. *Trends Pharmacol. Sci.* **32**, 521–33 (2011).
30. Wisler, J. J. *et al.* A unique mechanism of β -blocker action: Carvedilol stimulates β -arrestin signaling. *Proc. Natl Acad. Sci. USA* **104**, 16657–16662 (2007).
31. Drake, M. T. *et al.* β -arrestin-biased agonism at the β_2 -adrenergic receptor. *J. Biol. Chem.* **283**, 5669–76 (2008).
32. Urban, J. D. *et al.* Functional selectivity and classical concepts of quantitative pharmacology. *J. Pharmacol. Exp. Ther.* **320**, 1–13 (2007).
33. Deupi, X. & Standfuss, J. Structural insights into agonist-induced activation of G-protein-coupled receptors. *Curr. Opin. Struct. Biol.* **21**, 541–51 (2011).
34. Xu, F. *et al.* Structure of an agonist-bound human $\text{A}_{2\text{A}}$ adenosine receptor. *Science* **332**, 322–7 (2011).
35. Choe, H. W. *et al.* Crystal structure of metarhodopsin II. *Nature* **471**, 651–5 (2011).
36. Homer, R. J., Kim, M. S. & LeMaster, D. M. The use of cystathionine γ -synthase in the production of α and chiral β deuterated amino acids. *Anal. Biochem.* **215**, 211–5 (1993).
37. Schanda, P., Kupce, E. & Brutscher, B. SOFAST-HMQC experiments for recording two-dimensional heteronuclear correlation spectra of proteins within a few seconds. *J. Biomol. NMR* **33**, 199–211 (2005).
38. Davis, A. L., Keeler, J., Laue, E. D. & Moskau, D. Experiments for recording pure-absorption heteronuclear correlation spectra using pulsed field gradients. *J. Magn. Reson.* **98**, 207–216 (1992).
39. Kupce, E. & Freeman, R. Optimized adiabatic pulses for wideband spin inversion. *J. Magn. Reson. Ser. A* **118**, 299–303 (1996).
40. Emsley, L. & Bodenhausen, G. Optimization of shaped selective pulses for NMR using a quaternion description of their overall propagators. *J. Magn. Reson.* **97**, 135–148 (1992).

Acknowledgements

This work was supported by a grant from the Japan New Energy and Industrial Technology Development Organization (NEDO).

Author contributions

Y.K. designed the experiments, constructed the mutants for the resonance assignments, expressed and purified the labeled $\beta_2\text{AR}$, collected and processed the NMR data, performed the fluorescent and radioligand binding assays, and wrote the manuscript. T.U. designed the experiments, processed the NMR data, and wrote the manuscript. J.O. and Y.S. expressed and purified the non-labeled $\beta_2\text{AR}$. K.K. investigated the ^{13}C incorporation rates in thioredoxin. M.M. and H.T. constructed the plasmid, produced recombinant baculoviruses, and expressed the non-labeled $\beta_2\text{AR}$. I.S. supervised the overall project, designed the experiments, processed the NMR data, and wrote the manuscript.

Additional information

Supplementary Information accompanies this paper at <http://www.nature.com/naturecommunications>

Competing financial interests: The authors declare no competing financial interests.

Reprints and permission information is available online at <http://npg.nature.com/reprintsandpermissions/>

How to cite this article: Kofuku Y. *et al.* Efficacy of the β_2 -adrenergic receptor is determined by conformational equilibrium in the transmembrane region. *Nat. Commun.* **3**:1045 doi: 10.1038/ncomms2046 (2012).

License: This work is licensed under a Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit <http://creativecommons.org/licenses/by-nc-sa/3.0/>